Articles from Apollo Endosurgery, Inc.

Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™

AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQAPEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.

Systems Offer Effective, Minimally Invasive Treatment Options for Millions of Patients with Obesity (BMI 30-50 kg/m2)

Seasoned healthcare leader brings 30 years of hospital system and medical technology expertise

AUSTIN, TX / ACCESSWIRE / May 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights today from data presented at Digestive Disease Week May 21-24.

AUSTIN, TX / ACCESSWIRE / May 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that Apollo products and procedures that utilize Apollo products will be featured in more than 40 academic posters and videos and over 60 podium presentations and lectures at the upcoming Digestive Disease Week 2022 to be held in San Diego,

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (Nasdaq:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close. In conjunction with the release, Apollo will host a live

Veteran Brings 30 Years of Multinational Healthcare Leadership Experience AUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the

AUSTIN, TX / ACCESSWIRE / March 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that Chas McKhann, CEO, and Jeff Black, CFO, will host investor meetings March 7-8, 2022 as part of the Cowen Healthcare Conference, taking place virtually. As part of the conference event, management will participate in a fireside chat

- Increased adoption across all product lines in both U.S. and international - Grew fourth quarter 2021 revenue 26% AUSTIN, TX / ACCESSWIRE / February 22, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2021 and corporate highlights. Fourth Quarter and

AUSTIN, TX / ACCESSWIRE / February 10, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQAPEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the fourth quarter and full year ended December 31, 2021 on Tuesday, February 22, 2022, after market close. In conjunction with the release,

Veteran Leader Brings 25 Years of Global Medical Device Experience AUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022. "At Apollo, we are addressing large unmet clinical needs

Fourth quarter 2021 revenue grew 25% over 2020 AUSTIN, TX / ACCESSWIRE / January 10, 2022 / Apollo Endosurgery, Inc. ("Apollo" or the "Company") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2021. Preliminary, Unaudited 2021 Revenue Quarter Ended December 31, 2021 Year

- $35 million funded at close to refinance existing debt, extend maturity and lower interest expense - Additional borrowing capacity provides minimally dilutive growth capital and strategic flexibility AUSTIN, TX / ACCESSWIRE / December 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has entered into a debt

AUSTIN, TX / ACCESSWIRE / November 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that management will participate in four upcoming investor conference events. Conferences Apollo Endosurgery management will participate include: Monday, November 15, 2021 Stifel 2021 Healthcare Conference (Virtual) Management will

AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights. Third Quarter 2021 Selected Financial Results - Total revenue of $16.4 million, an increase of 28% compared to the third quarter of 2020 -

Study demonstrates high success rates, ease of use, and economic value in the treatment of GI defects AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the publication of a multi-center study of the X-Tack®System in closing challenging gastrointestinal defects. Removal of

AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQAPEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes. In conjunction with the release, Apollo will

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the pricing of its previously announced underwritten public offering. Apollo is selling 8,400,000 shares of its common stock at a public offering price of $7.75 per share for gross proceeds of approximately $65 million, before deducting

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriters a 30-day option to purchase additional

- Revenue expected between $16.0 million and $16.4 million - Third consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30% - Submitted a De Novo 510(k) Classification Request to FDA for Apollo ESG™ for weight loss and Apollo REVISE™ for prior bariatric surgery revisions - Principal investigators expected to present primary efficacy and safety endpoints from MERIT study in late October AUSTIN, TX /

AUSTIN, TX / ACCESSWIRE / September 13, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in Lake Street's 5th Annual Best Ideas Growth Conference. September 14-15, 2021 Lake Street's 5th Annual Best Ideas Growth Conference Management teams from over 100 dynamic small-cap publicly

AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021. Highlights - Achieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the Company* - Increased Endoscopic

AUSTIN, TX / ACCESSWIRE / July 27, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2021 on Tuesday, August 3, 2021 after the market closes. In conjunction with the release, Apollo will host a conference

Veteran Executive Brings 30 Years of Financial and Operational Leadership Experience AUSTIN, TX / ACCESSWIRE / July 16, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Jeffrey G. Black as Chief Financial Officer. Mr. Black has served as Chief Financial Officer for a variety of publicly-traded companies in

AUSTIN, TX / ACCESSWIRE / June 14, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study have reported based on a preliminary analysis the successful achievement of the study's primary endpoints. In a presentation at the 2021 Surgical Disruptive

AUSTIN, TX / ACCESSWWIRE / June 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that management will participate in two investor conference events during the month of June 2021. Conferences Apollo Endosurgery management will participate include: Wednesday, June 2, 2021 18th Annual Craig-Hallum

AUSTIN, TX / ACCESSWIRE / May 24, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights from Digestive Disease Week (DDW) 2021 which was held May 21-23. During the 3-day virtual event, there were more than 30 different presentations featuring the use of the OverStitch™ Endoscopic Suturing System in a

AUSTIN, TX / ACCESSWIRE / May 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the Sidoti & Company Virtual Microcap Conference on May 20, 2021. Management will present an overview presentation on Thursday, May 20, at 10:00 am Eastern Standard Time. A live and archive webcast link to

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / May 4, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2021. Highlights - Total revenue of $13.9 million, an increase of 29% from the first

Kirk Ellis to Serve as Vice President of US Sales Steve Bosrock to Serve as Vice President of Marketing & Medical Education AUSTIN, TX / ACCESSWIRE / May 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointments of Kirk Ellis as Vice President of US Sales and Steve Bosrock as Vice

AUSTIN, TX / ACCESSWIRE / April 28, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQAPEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after the market closes. In conjunction with the release, Apollo will host a

Authors conclude, "Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation." AUSTIN, TX / ACCESSWIRE / April 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the publication of supporting pre-clinical results for the